Single Cell Analysis Market Report Sixth Edition, 2024-2029
Report Summary
The single cell analysis (SCA) market, which is increasingly established, is comprised of sequencing (i.e., that assess nucleic acids such as DNA or RNA) and proteomic technologies that assess analytes at the level of single cells, rather than at the level of an entire cell population.
The sixth edition of this report takes a completely updated and comprehensive look at the SCA market. We assess the SCA market across 6 segments and 31 subsegments: customer (academia, biopharma, applied markets, clinical), workflow step (e.g., tissue dissociation, sample preparation, downstream analysis), analyte (e.g., RNA, DNA, epigenetic, protein, multiomic, other), field-of-study (e.g., oncology, basic cell biology, stem cell biology, microbiology, neurology, immunology, other, non-specific), product type (e.g.,instruments, reagents, services, other) and geography (e.g., U.S., Europe, China, Asia-Pacific, ROW). For each of these segments, we provide an estimated market size and growth from 2024 to 2029, as well as key growth drivers and moderators.
We review key factors driving future growth including 1) Growing acceptance of the maturity of SCA technology, particularly for scRNA-seq, driving broader adoption among new users in academia and expanded use within pharma 2) Users across academia and biopharma taking advantage of falling assay and sequencing costs to run higher throughput experiments in terms of both sample volumes (e.g., 20-100) and cell volumes (e.g., 1M+) 3) Increasing use of FFPE-based assays by biopharma, particularly those that had been waiting for sufficient validation data in previous years and 4) Growing interest in multiomic-based SCA, especially ATAC + RNA multiomic analysis and CITE-seq, as users look to tie findings across –omics classes together. On the other hand, we discuss key factors moderating growth including 1) Increasing competition with spatial-omics for tissue-based samples 2) Growing competition within the SCA market, as well as initial traction for instrument-free approaches, has put downward pressure on reagent and instrument pricing 3) A lack of a clear and unique clinical application for SCA, limiting use to earlier stages of R&D / trials.
In addition, we include output from a primary research campaign across 80 single cell researchers in academia, biopharma, and clinical settings. We capture current and anticipated spend, analyte trends (e.g., RNA, DNA, multiomics), platform acquisition trends (i.e., plans on buying additional instruments), and vendor feedback.
Report Scope
Technologies and Revenues Included:
- Single cell analysis – the study of single cell biology, primarily using sequencing-based analysis of analytes (e.g., RNA / DNA sequencing); analysis can also include other molecular signatures (e.g., protein, epigenetic, multiomic)
- Tissue dissociation, sample preparation (including single cell isolation),and downstream analysis spend
- Instrument & reagent revenues associated with the purchase of single cell analysis platforms or reagents / kits used to run the assays, and service revenues to SCA tools manufacturers
- Sales of products to academic, biotech /pharmaceutical companies, and CRO customers
Technologies and Revenues Excluded:
- Spatial analysis tools are not accounted for in this report (e.g., 10x estimated spatial revenue is subtracted to estimate single cell revenues only)
- Specialized bioinformatics offerings that are not provided by the SCA platform / vendor
- Flow cytometry analysis that does not involve single cell sequencing
Report Update
New to the 6th Edition:
- Expanded survey, featuring 30+ slides of data synthesized from 80 respondents
- New Emerging SCA Technologies section, featuring an analysis of instrument-free, multiomic, and functional SCA assays
- Primary vendor feedback on 25 competitors in the space (Global License only)
Updated Content
- Incorporated the latest trends in the SCA market, based on interviews (N=29) with experts, a survey spanning academia and biopharma (N=80), and extensive secondary research
- Assessed new / current offerings and expected future portfolio developments
- Updated market sizing, segmentation, and forecast based on primary research findings and publicly-available financials
- Evaluated emerging technologies in depth, highlighting key vendors and applications (e.g., instrument-free platforms, functional SCA, multiomic assays)
Table of Contents
- Introduction
- Executive Summary
- Competitive Market Analysis
- Market Analysis
- Emerging Single Cell Technologies
- Publication Analysis
- Primary Market Research
- Primary Vendor Feedback (Global License Only)
- Company Profiles
- Appendix
Survey
The focus of this survey was to characterize the current use (or lack thereof) of single cell analysis across academia, biopharma, and CROs. Respondents were asked about their current use of SCA, including any instrument-free vendors, as well as expectations for future use over the next 12 months
The survey was distributed randomly to current SCA users; respondents vary from new adopters to highly established genomics core laboratories.
Survey Participants were asked about:
- Traditional single cell technologies (e.g.,single cell RNA-seq), including use of different vendors, the number of instruments in their lab, instrument utility, and reasons for using SCA
- Multi-omic single cell analysis (e.g., RNA +protein, RNA + DNA, etc.)
- Instrument-free platforms (e.g., Parse Biosciences’ Evercode, etc.), including reasons for adoption, expected adoption timeframe, and satisfaction with current instrument-free platforms
- Functional single cell analysis utilization
The single cell analysis (SCA) market, which is fast growing and increasingly more established, is comprised of sequencing (i.e., that assess nucleic acids such as DNA or RNA) and proteomic technologies that assess analytes at the level of single cells, rather than at the level of an entire cell population.
The sixth edition of this report takes a completely updated and comprehensive look at the SCA market. We assess the SCA market across 6 segments and 31 subsegments: customer (academia, biopharma, applied markets, clinical), workflow step (e.g., tissue dissociation, sample preparation, downstream analysis), analyte (e.g., RNA, DNA, epigenetic, protein, multiomic, other), field-of-study (e.g., oncology, basic cell biology, stem cell biology, microbiology, neurology, immunology, other, non-specific), product type (e.g., instruments, reagents, services, other) and geography (e.g., U.S., Europe, China, Asia-Pacific, ROW). For each of these segments, we provide an estimated market size and growth from 2024 to 2029, as well as key growth drivers and moderators.
The Sixth Edition of this report has been expanded to cover each segment of the market in greater detail. New sections featured in the Sixth Edition include an in-depth competitive market analysis by each step of the single cell workflow, a section covering emerging single cell analysis technologies (e.g., instrument-free, multiomic, and functional single cell analysis), as well as an expanded end-user survey of 75+ stakeholders across academia, biopharma, and CROs.
Segmentations Covered in Market Analysis
Customer: Buyers of SCA instruments, reagents, and consumables from manufacturers
- Academia
- Biopharma
- Applied Markets
- Clinical
Workflow: Individual steps in the SCA process starting from sample and ending with data
- Tissue Dissociation
- Sample Preparation
- Downstream Analysis
Analyte: Application / analyte that is detected
- RNA
- DNA
- Epigenetic
- Protein
- Multiomic
- Other
Field-of-Study: Research focus including broad non-disease specific biological area as well as specific disease areas
- Oncology
- Immunology
- Microbiology
- Basic cell biology
- Stem cell biology
- Neurology
- Other
- Non-specific
Product Type: Type of product that manufacturer sells to its customers
- Instruments (including systems, service contract, and software)
- Reagents (including reagents and consumables)
- Services
- Other
Geography: Country / region of the world
- U.S.
- Europe
- China
- Asia Pacific (APAC)
- Rest-of-the-world (ROW)
Companies Profiled in Competitive Analysis
- 10x Genomics
- BD
- Bruker
- Illumina
- MGI
- Mission Bio
- Parse Biosciences
- Takara Bio
- Scale Biosciences
- Singleron
- Others
Purchase Options
Experience the DeciBio Difference
Experience the DeciBio Difference
- $ 7,500.00 USD
- $ 11,000.00 USD
- $ 13,000.00 USD
- $ 5,000.00 USD
